Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients
Primary Purpose
Hypothyroidism
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)
levothyroxin
Sponsored by
About this trial
This is an interventional other trial for Hypothyroidism
Eligibility Criteria
Inclusion Criteria:
- primary hypothyroidism on LT4 replacement therapy
- TSH, fT3 and fT4 in the normal range
- stable LT4 dosage during the previous six months before enrolment
- Caucasian ethnicity
Exclusion Criteria:
- total thyroidectomy for thyroid carcinoma
- high fiber diet
- intestinal malabsorption (e.g. bariatric surgery, inflammatory bowel diseases, coeliac disease)
- ongoing therapies interfering with LT4 absorption and/or metabolism (i.e. aluminium-containing antacids, sucralfate, proton pump inhibitors, calcium carbonate, raloxifene, bile acids sequestrants and ferrous sulfate)
- antibiotics treatment in the previous six months before enrolment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Probiotics
Levothyroxine
Arm Description
The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
The control group took levothyroxine only
Outcomes
Primary Outcome Measures
differences in thyroid-stimulating hormone (TSH) serum levels comparing study group and controls
measurement of serum levels of thyroid-stimulating hormone (TSH) - unit of measure: microIU/mL, normal range: 0.35-4.94
Secondary Outcome Measures
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of total cholesterol (CH) - unit of measure: mg/dL, normal range: <200
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of sex hormone-binding globulin (SHBG) - unit of measure: nmol/L, normal range: males 13.5-71.4, females 19.8-155.2
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of ferritin - unit of measure: ng/mL, normal range: 25-400
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of creatine phosphokinase (CPK) - unit of measure: U/L, normal range: 10-71
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of myoglobin - unit of measure: ng/mL, normal range: 15-106
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of osteocalcin - unit of measure: ng/mL, normal range: 4.6-65.4
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of angiotensin-converting enzyme (ACE) - unit of measure: U/L, normal range: 8-52
differences in thyroid hormones by biochemical assays comparing study group and controls
measurement of serum levels of free triiodothyronine (fT3) - unit of measure: pg/mL, normal range: 1.7-3.7; measurement of serum levels of free thyroxine (fT4) - unit of measure: pg/mL, normal range: 7-15
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03095963
Brief Title
Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients
Official Title
Effects of Probiotics Assumption on Serum Thyroid Hormone and TSH Levels in Hypothyroid Patients on Levothyroxine Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
January 1, 2014 (undefined)
Primary Completion Date
October 25, 2016 (Actual)
Study Completion Date
October 25, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda USL Modena
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
A prospective, randomized, single-blind, controlled, investigator-started clinical trial was carried out. Patients with primary hypothyroidism were randomly assigned to the study (VSL#3®+ LT4) and the control group (LT4). A two months treatment phase was followed by two months of follow-up. Clinical examination, blood tests for thyroid function and for peripheral tissue markers of thyroid hormones effect were performed monthly for 4 months. LT4 dose adjustments were performed during the study when necessary.
Detailed Description
Consecutive patients on LT4 replacement therapy attending the Endocrinology Unit of Modena (Italy) were screened. According to inclusion and exclusion criteria, eighty participants were enrolled and randomized in study or control group. The random allocation sequence was generated using 'Statistical Package for the Social Sciences' software for Macintosh (SPSS) considering a 1:1 ratio by the statistician of the Unit. Clinicians evaluating and enrolling patients were blinded to the randomization list. The study design provided a monthly visit for a 4 months overall time-frame. Patients assigned to the study group took the probiotic supplement VSL#3® for two months, followed by a two months period of follow-up. Study group patients were taught to assume the probiotic supplement at least two hours after LT4 administration, to dissolve it in a cold beverage and to store it in a refrigerator (2°-8°C) in order to preserve bacteria load. The study design was single-blind since only the clinician was aware of the allocation. The VSL#3® administration was provided by nurses. Participants were invited to return all used and unused sachets to count the number of opened sachets per the number of treatment days.
All patients underwent five visits (baseline, visit 1, 2, 3 and 4) in which anthropometrical evaluation (weight and height) and hormonal function assessment were performed. A blood sample was taken in the morning at each visit, on empty stomach and before LT4 ingestion. In occurrence of hormonal alteration, LT4 daily dose was adjusted according to clinical guidelines. At baseline, visit 2 and visit 4, patients underwent clinical examination with heart rate and blood pressure evaluation. During each visit, the following data were collected: probiotic assumption, sex, age, hypothyroidism aetiology, LT4 formulation dose and brand, body mass index (BMI), body surface area (BSA), systolic blood pressure, diastolic blood pressure, heart rate, TSH, fT4, fT3 and any possible LT4 posology adjustment. All the clinical data have been further databased.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypothyroidism
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Probiotics
Arm Type
Active Comparator
Arm Description
The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
Arm Title
Levothyroxine
Arm Type
Active Comparator
Arm Description
The control group took levothyroxine only
Intervention Type
Other
Intervention Name(s)
a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)
Intervention Description
Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
Intervention Type
Drug
Intervention Name(s)
levothyroxin
Intervention Description
replacement therapy for hypothyroidism
Primary Outcome Measure Information:
Title
differences in thyroid-stimulating hormone (TSH) serum levels comparing study group and controls
Description
measurement of serum levels of thyroid-stimulating hormone (TSH) - unit of measure: microIU/mL, normal range: 0.35-4.94
Time Frame
Through study completion, an average of 4 months
Secondary Outcome Measure Information:
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of total cholesterol (CH) - unit of measure: mg/dL, normal range: <200
Time Frame
Through study completion, an average of 4 months
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of sex hormone-binding globulin (SHBG) - unit of measure: nmol/L, normal range: males 13.5-71.4, females 19.8-155.2
Time Frame
Through study completion, an average of 4 months
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of ferritin - unit of measure: ng/mL, normal range: 25-400
Time Frame
Through study completion, an average of 4 months
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of creatine phosphokinase (CPK) - unit of measure: U/L, normal range: 10-71
Time Frame
Through study completion, an average of 4 months
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of myoglobin - unit of measure: ng/mL, normal range: 15-106
Time Frame
Through study completion, an average of 4 months
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of osteocalcin - unit of measure: ng/mL, normal range: 4.6-65.4
Time Frame
Through study completion, an average of 4 months
Title
differences in peripheral tissue markers of thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of angiotensin-converting enzyme (ACE) - unit of measure: U/L, normal range: 8-52
Time Frame
Through study completion, an average of 4 months
Title
differences in thyroid hormones by biochemical assays comparing study group and controls
Description
measurement of serum levels of free triiodothyronine (fT3) - unit of measure: pg/mL, normal range: 1.7-3.7; measurement of serum levels of free thyroxine (fT4) - unit of measure: pg/mL, normal range: 7-15
Time Frame
Through study completion, an average of 4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
primary hypothyroidism on LT4 replacement therapy
TSH, fT3 and fT4 in the normal range
stable LT4 dosage during the previous six months before enrolment
Caucasian ethnicity
Exclusion Criteria:
total thyroidectomy for thyroid carcinoma
high fiber diet
intestinal malabsorption (e.g. bariatric surgery, inflammatory bowel diseases, coeliac disease)
ongoing therapies interfering with LT4 absorption and/or metabolism (i.e. aluminium-containing antacids, sucralfate, proton pump inhibitors, calcium carbonate, raloxifene, bile acids sequestrants and ferrous sulfate)
antibiotics treatment in the previous six months before enrolment
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29184537
Citation
Spaggiari G, Brigante G, De Vincentis S, Cattini U, Roli L, De Santis MC, Baraldi E, Tagliavini S, Varani M, Trenti T, Rochira V, Simoni M, Santi D. Probiotics Ingestion Does Not Directly Affect Thyroid Hormonal Parameters in Hypothyroid Patients on Levothyroxine Treatment. Front Endocrinol (Lausanne). 2017 Nov 14;8:316. doi: 10.3389/fendo.2017.00316. eCollection 2017.
Results Reference
derived
Learn more about this trial
Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients
We'll reach out to this number within 24 hrs